

Name of the Issue: Indegene Limited

Last Updated on: November 13, 2025

1 Type of Issue (IPO/FPO) IPO

2 Issue Size (Rs. Cr) 1841.75

\* As per Basis of Allotment

3 Grade of issue along with name of the rating agency

Name Not Applicable

Grade Not Applicable

4 Subscription Level (Number of times): 70.85

\*The above figure is after technical rejection and excludes anchor allotment

Source: Minutes of Basis of Allotment

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	8.46%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (Jun 30, 2024)	7.63%
(iii) at the end of 1st FY (March 31, 2025)	10.20%
(iv) at the end of 2nd FY (March 31, 2026)#	Not Available
(v) at the end of 3rd FY (March 31, 2027)#	Not Available

\* As per the Basis of Allotment

# QIB Holding not disclosed as reporting for relevant fiscal years have not been completed/ not publicly available

Source:

(1) Basis of Allotment

(2) Reported to the stock exchanges;

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Crore)

Parameters (Consolidated)	1st FY (March 31, 2025)	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from operations	2,839.3	Not Available	Not Available
Net Profit for the period	406.7	Not Available	Not Available
Paid-up equity share capital	47.9	Not Available	Not Available
Reserves excluding revaluation reserves	2,567.7	Not Available	Not Available

\* Financials not disclosed as reporting for the fiscal year has not been completed / not publicly available

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.

The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2026)*	Not Applicable
(iii) at the end of 3rd FY (March 31, 2027)*	Not Applicable

\* Trading status not disclosed as the relevant fiscal year has not been completed

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available

\*Changes in Directors not disclosed as the relevant fiscal year has not been completed

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - Not Applicable  
(ii) Actual implementation - Not Applicable  
(iii) Reasons for delay in implementation, if any - Not Applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document (Rs. Crore)

Particulars	Proposed utilization	Actual utilization
Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings, Inc	391.34	395.00
Funding the capital expenditure requirements of our Company and one of our Material Subsidiaries, Indegene, Inc	102.92	18.47
General corporate purposes and inorganic growth	230.12	246.79
<b>Total</b>	<b>724.37</b>	<b>660.26</b>

- (ii) Actual utilization - Please reference the table above  
(iii) Reasons for deviation, if any - Not Applicable

11 Comments of monitoring agency, if applicable

Not Applicable

12 Pricing Data

Issue Price (Rs.): 452  
Designated Stock Exchange: NSE  
Listing Date: 13-May-24

Price parameters	At close of listing day (May 13, 2024)	At close of 30th calendar day from listing day <sup>(1)</sup> (Jun 11, 2024)	At close of 90th calendar day from listing day <sup>(2)</sup> (Aug 10, 2024)	As at the end of 1st FY after the listing of the issue (March 31, 2025)			As at the end of 2nd FY after the listing of the issue (March 31, 2026) <sup>(3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2027) <sup>(3)</sup>		
				Closing price	High (during the FY)*	Low (during the FY)*	Closing price	High (during the FY)*	Low (during the FY)*	Closing price	High (during the FY)*	Low (during the FY)*
Market Price (on NSE)	570.90	561.75	573.4	578.5	736.3	470.1	N.A	N.A	N.A	N.A	N.A	N.A
Nifty 50	22,104.05	23,264.85	24,367.50	23,519.4	26,277.4	21,281.5	N.A	N.A	N.A	N.A	N.A	N.A
Sectoral Index	N.A.	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website

(1) 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(2) 90th calendar day has been taken as listing date plus 89 calendar days, except where 90th,calendar day is a holiday, in which case we have considered the closing data of the previous trading day

(3) Pricing data not disclosed as the relevant fiscal year has not completed.

\* Intraday high and low prices considered

### 13 Basis for Issue Price

Accounting ratio		As disclosed in the offer document dated May 13, 2024	At the end of 1st FY (March 31, 2025)	At the end of 2nd FY (March 31, 2026)*	At the end of 3rd FY (March 31, 2027)*
Diluted EPS (Rs.):	Issuer <sup>(1)</sup> :	11.97	17.02	Not Available	Not Available
	Peer Group:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Available	Not Available	Not Available
P/E	Issuer <sup>(1)</sup> :	37.76x	33.99x	Not Available	Not Available
	Peer Group:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
RoNW (%)	Issuer <sup>(1)</sup> :	27.37%	16.5%	Not Available	Not Available
	Peer Group:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NAV per share based on last balance sheet	Issuer <sup>(1)</sup> :	59.86	103.0	Not Available	Not Available
	Peer Group:	Not Applicable	Not Applicable	Not Applicable	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Source: Prospectus

(1) Financial information for the Company is on a consolidated basis

Prospectus has not provided any industry comparison in relation to this Company

\* Not available as reporting for the relevant period has not been completed / not available publicly

### 14 Any other material information

Particulars	Date
Received approval from the Board for investment in Indegene Ireland, a wholly owned subsidiary, up to an amount of EUR 8.5mm	31-Oct-25
Announced acquisition of BioPharm to expand AI-driven marketing and AdTech for Global Pharma	1-Oct-25
Secondary sell-down by CA Dawn	5-Jun-25
Secondary sell-down by Catalyst Trusteeship Ltd	5-Jun-25
Secondary sell-down by Deutsche Bank AG	5-Jun-25
Announced a dividend of Rs.2 / share for the financial year ended March 31, 2025	28-Apr-25
The Board of Directors announced the allotment of shares under ESOP 2020 plan	21-Apr-25
The Board of Directors approved investment in equity/preference shares of Indegene Ireland Limited to support the subsidiary's capex requirements	25-Mar-25
Acquired 100% stake of MJL, which specializes in brand strategy, omnichannel campaigns, and patient engagement	19-Mar-25
Company announced expansion of international footprint with launch of new centre in London	19-Mar-25
Announced the re-appointment of Jairaj Manohar Purandare, Ashish Gupta and Pravin Udhayavara Bhadya Rao as directors	17-Mar-25
Company received award for Winner of Enterprise Growth Awards 2025 from Deloitte	10-Mar-25
Indegene announced launch of Cortex, A Fit-For- Purpose Generative AI platform, Verticalized For The Life Sciences Industry	24-Feb-25
Company issued press release titled "Everest Group Recognizes Indegene as a Front-Runner in GenAI Life Sciences Market Adoption"	11-Feb-25
Company announced launch of new entity in Spain	6-Feb-25
Indegene announced receipt of big innovation award for 2025	17-Jan-25
Intimation of outcome of Resolution by Circulation: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, the resolutions are passed by the Directors of Indegene Limited by circulation on November 18, 2024 in relation to allot shares under ESOP / RSU 2020 plan	22-Nov-24
Indegene Expands Global Delivery Network, Announces A New Center in Hyderabad	18-Nov-24
Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd This disclosure is in respect of release of encumbrance by way of release of pledge over the pledged shares created by CA Dawn in favor of the Onshore Security Agent for the benefit of the lenders	12-Nov-24
Intimation of Monitoring Agency Report for the quarter ended September 30, 2024	29-Oct-24
Released - Analyst presentation and fact sheet on financial results for the quarter ended September 30, 2024	28-Oct-24
Intimation of Monitoring Agency Report for the quarter ended June 30, 2024	8-Aug-24
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held on August 1, 2024	6-Aug-24
Annual Report with Notice of Annual General Meeting of FY 23-24	13-Aug-24

Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)